FOXD1 and prostate carcinoma: The identification of FOXDs as candidate Wnt pathway activators is consistent with the recent observation that silencing of FOXD1 lowered β-catenin levels in prostate cancer cells and concomitantly decreased cell proliferation and invasion (33).